https://www.businesswire.com/news/home/20200603005084/en/Fractyl-Announces-FDA-IDE-Approval-to-Begin-Pivotal-Study-of-Revita-DMR-for-Insulin-Treated-Patients-with-Type-2-Diabetes
Fractyl Announces FDA IDE Approval to Begin Pivotal Study of Revita DMR for Insulin-Treated...
Fractyl to begin pivotal study for type 2 diabetes to evaluate the ability of Revita DMR to reduce or eliminate the need for insulin injections.
https://pro.thestreet.com/thefly-newsbreaks/guts-fractyl-health-price-target-lowered-by-at-bofa-heres-why
Fractyl Health price target lowered by $4 at BofA, here's why | TheStreet Pro
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's...
https://www.fractyl.com/
Home | Fractyl Health
Dec 2, 2025 - Break the Pattern of Obesity and Type 2 Diabetes People struggling with obesity and type 2 diabetes are caught in a relentless cycle of disease progression...
health
https://www.nasdaq.com/market-activity/stocks/guts/price-earnings-peg-ratios
Fractyl Health, Inc. Common Stock (GUTS) Price/Earnings & PEG Ratios | Nasdaq
Get updated information on Fractyl Health, Inc. Common Stock (GUTS) Price/Earnings Ratio (or PE Ratio) and PEG ratio for stock evaluations with Nasdaq.
common stockhealthinc
https://www.techtarget.com/pharmalifesciences/news/366637979/Fractyl-Healths-Revita-reduces-post-GLP-1-weight-regain-by-70
Fractyl Health's Revita reduces post-GLP-1 weight regain by ~70% | TechTarget
Fractyl Health's outpatient endoscopic procedure, Revita, reduces post-GLP-1 weight regain by ~70% after 6 months, midpoint cohort data shows.
https://www.businesswire.com/news/home/20200128005258/en/Fractyl-Announces-First-Ever-Commercial-Availability-of-Revita-for-Type-2-Diabetes-in-Partnership-with-Leading-UK-Private-Clinic
Fractyl Announces First-Ever Commercial Availability of Revita for Type 2 Diabetes in Partnership...
Revita, a first-in-class treatment for type 2 diabetes, is commercially available for the first time ever via a partnership with HCA Healthcare UK.
https://health.economictimes.indiatimes.com/news/pharma/pharma-industry/fractyl-health-targets-up-to-762-mln-valuation-in-us-ipo/107257865
Fractyl Health targets up to $762 mln valuation in US IPO, ETHealthworld
Fractyl Health: The U.S. IPO market is looking to rebound in 2024 after two subpar years as hopes of a soft landing for the economy grow. Last week, Healthcare...
health targetsup to